Inventor

FREY II WILLIAM H

US54 patents

⚠️ This page may combine multiple inventors who share the name “FREY II WILLIAM H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

FREY II WILLIAM H

HEALTHPARTNERS RES FOUNDATION

Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent

Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia

Methods and compositions for enhancing cellular function through protection of tissue components

Method of treating Alzheimer&#39;s disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity

Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog

Methods of treating Huntington&#39;s disease comprising administering metal chelators to the upper one-third of the nasal cavity

Methods of treating neurodegeneration caused by iron accumulation in the brain comprising administering metal chelators to the upper one-third of the nasal cavity

Method of treating lewy body syndrome comprising administering metal chelators to the upper one-third of the nasal cavity

Method of treating stroke comprising administering metal chelators to the upper one-third of the nasal cavity

FREY II WILLIAM H

Device and method for delivering therapeutic substances to the maxillary sinus of a patient

Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions

Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning

Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog

Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection

Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage

Pharmaceutical compositions for treatment of patients with neurodegeneration following ischemic insult

Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

CHIRON CORP

Method for administering insulin to the brain

Method for administering neurologic agents to the brain

Method for administering a cytokine to the central nervous system and the lymphatic system

Method for administering fibroblast growth factor to the brain

Method for administering insulin-like growth factor to the brain

Method for administering agents to the central nervous system

YEOMANS DAVID C

Methods for treatment of headaches by administration of oxytocin

Methods for treatment of headaches by administration of oxytocin

Therapy procedure for drug delivery for trigeminal pain

Methods for treatment of headaches by administration of oxytocin

Methods for treatment of headaches by administration of oxytocin

HEALTHPARTNERS RES & EDUCATION

Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin

Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin

Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin

Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin

Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin

HEALTHPARTNERS INST

Methods for treating patients with impaired awareness of hypoglycemia

Methods of treating anorexia nervosa by intranasal administration of insulin

Method of treating cerebral hemorrhage and subarachnoid hemorrhage comprising administering metal chelators to the upper one-third of the nasal cavity

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system

HEALTHPARTNERS RES FOUND

Method of pre-treating patients for stroke comprising administering metal chelators to the upper one-third of the nasal cavity

Method of treating traumatic brain injury/head injury comprising administering metal chelators to the upper one-third of the nasal cavity

Method of treating spinal cord injury comprising administering metal chelators to the upper one-third of the nasal cavity

Method of treating progressive supranuclear palsy comprising administering metal chelators to the upper one-third of the nasal cavity

TAKEDA PHARMACEUTICALS CO

Treatment of central nervous system disorders by intranasal administration of immunoglobulin G

Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

RAMSEY FOUNDATION

Method for administering neurologic agents to the brain

UNIV MINNESOTA

Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

BAXALTA INC

Treatment of central nervous system disorders by intranasal administration of immunoglobulin G

WOLF DANIEL A

Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

DEEN DENNIS F

CNS-tumor treatment method and composition

BRESIN HANSON LEAH RANAE

Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders

Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity

Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity